Advanced search
1 file | 1.39 MB Add to list

To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition

Author
Organization
Abstract
Objectives: Assessing the safety and efficacy of immune checkpoint inhibition in risky cancer patient subgroups: pre-existing organ failure, elderly, presence of auto-immune disease, transplanted patients and brain metastasis treated with immune checkpoint inhibitors. Methods: PubMed, Web of Science and Google scholar databases were searched for English articles published prior to February 2019. Search terms used were organ failure, dialysis, elderly, organ transplant, liver disease, auto-immune disease, immunosuppression, and brain metastasis. Results: Our literature data indicate that immune checkpoint inhibition in the majority of these subpopulations can be administered safely without any loss of efficacy. These data are mostly based on case-reports as only a minority of high-risk patients were included in (the earliest) clinical trials. Validation of these results is necessary on a larger scale. Conclusion: Future trials should not automatically exclude aforementioned patient groups but alter the study design and make their inclusion possible, since more data are needed to answer several remaining questions in these populations. Especially since ICI appears to be safe to administer in these patients.
Keywords
Immune checkpoint inhibition, organ failure, elderly, autoimmune disease, brain metastasis, organ transplant patients, ADVERSE EVENTS, PREEXISTING AUTOIMMUNE, EFFICACY, COMPLICATIONS, ATEZOLIZUMAB, MULTICENTER, IPILIMUMAB, CARCINOMA, NIVOLUMAB, BLOCKADE

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.39 MB

Citation

Please use this url to cite or link to this publication:

MLA
De Keukeleire, Stijn, et al. “To Treat or Not to Treat? Managing Comorbidities in Cancer Patients under Immune Checkpoint Inhibition.” ACTA CLINICA BELGICA, 2019.
APA
De Keukeleire, S., Vermassen, T., De Schoenmakere, G., Kruse, V., Vermaelen, K., & Rottey, S. (2019). To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. ACTA CLINICA BELGICA.
Chicago author-date
De Keukeleire, Stijn, Tijl Vermassen, Gert De Schoenmakere, Vibeke Kruse, Karim Vermaelen, and Sylvie Rottey. 2019. “To Treat or Not to Treat? Managing Comorbidities in Cancer Patients under Immune Checkpoint Inhibition.” ACTA CLINICA BELGICA.
Chicago author-date (all authors)
De Keukeleire, Stijn, Tijl Vermassen, Gert De Schoenmakere, Vibeke Kruse, Karim Vermaelen, and Sylvie Rottey. 2019. “To Treat or Not to Treat? Managing Comorbidities in Cancer Patients under Immune Checkpoint Inhibition.” ACTA CLINICA BELGICA.
Vancouver
1.
De Keukeleire S, Vermassen T, De Schoenmakere G, Kruse V, Vermaelen K, Rottey S. To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. ACTA CLINICA BELGICA. 2019;
IEEE
[1]
S. De Keukeleire, T. Vermassen, G. De Schoenmakere, V. Kruse, K. Vermaelen, and S. Rottey, “To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition,” ACTA CLINICA BELGICA, 2019.
@article{8646323,
  abstract     = {Objectives: Assessing the safety and efficacy of immune checkpoint inhibition in risky cancer patient subgroups: pre-existing organ failure, elderly, presence of auto-immune disease, transplanted patients and brain metastasis treated with immune checkpoint inhibitors. Methods: PubMed, Web of Science and Google scholar databases were searched for English articles published prior to February 2019. Search terms used were organ failure, dialysis, elderly, organ transplant, liver disease, auto-immune disease, immunosuppression, and brain metastasis. Results: Our literature data indicate that immune checkpoint inhibition in the majority of these subpopulations can be administered safely without any loss of efficacy. These data are mostly based on case-reports as only a minority of high-risk patients were included in (the earliest) clinical trials. Validation of these results is necessary on a larger scale. Conclusion: Future trials should not automatically exclude aforementioned patient groups but alter the study design and make their inclusion possible, since more data are needed to answer several remaining questions in these populations. Especially since ICI appears to be safe to administer in these patients.},
  author       = {De Keukeleire, Stijn and Vermassen, Tijl and De Schoenmakere, Gert and Kruse, Vibeke and Vermaelen, Karim and Rottey, Sylvie},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {Immune checkpoint inhibition,organ failure,elderly,autoimmune disease,brain metastasis,organ transplant patients,ADVERSE EVENTS,PREEXISTING AUTOIMMUNE,EFFICACY,COMPLICATIONS,ATEZOLIZUMAB,MULTICENTER,IPILIMUMAB,CARCINOMA,NIVOLUMAB,BLOCKADE},
  language     = {eng},
  pages        = {9},
  title        = {To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition},
  url          = {http://dx.doi.org/10.1080/17843286.2019.1646516},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: